Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in alzheimer disease
Tóm tắt
Alzheimer disease (AD) is the most common neurodegenerative disease, affecting approx 4 million people in the United States in the year 2000 alone. Amyloid β (Aβ) deposition, activated glial cells, and neuritic degeneration are the characteristic features of AD. Although the precise cause of AD has yet to be determined, a bulk of evidence suggests that inflammatory responses elicited by elevated Aβ peptides play an important role in the pathogenic process of the disease. In AD brain, mononuclear phagocytes (microglia) accumulate at the sites of Aβ peptide deposition. In vitro, Aβ peptides activate mononuclear phagocytes to release neurotoxic mediators. A number of cell-surface molecules have been reported to act as putative receptors for A β peptides, among which the G protein—coupled formyl peptide receptor—like 1 (FPRL1) and its mouse homolog FPR2 have been shown to be expressed by activated microglial cells and mediate the chemotactic activity of the 42 amino acid form of A β (Aβ42). FPRL1 also participates in A β42 internalization in macrophages and its cytotoxicity for neuronal cells. Therefore, FPRL1 may be involved in the inflammatory aspects of AD. This review discusses recent findings relevant to the function and regulation of FPRL1/FPR2 in mononuclear phagocytes by pro- and antiinflammatory signals and its potential as a therapeutic target in AD.
Tài liệu tham khảo
Chao CC, Hu S, Peterson PK: Glia: the not so innocent bystanders. J Neurovirol 1996;2:234–239.
Del Rio Hortega P: Microglia; in Penfield W (ed): Cytology and Cellular Pathology of the Nervous System. New York, Paul Hoeber 1932, pp 481–534.
Lawson LJ, Perry VH, Dri P, Gordon S: Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990;39:151–170.
Perry VH: Microglia resident macrophages of the CNS; in Perry VH (ed): Macrophages and the Nervous System. Austin, TX, RG Landes 1994, pp 6–27.
Fedoroff S, Zhai R, Novak JP: Microglia and astroglia have a common progenitor cell. J Neurosci Res 1997;50:477–486.
Flaris NA, Densmore TL, Molleston MC, Hickey WF: Characterization of microglia and macrophages in the central nervous system of rats: definition of the differential expression of molecules using standard and novel monoclonal antibodies in normal CNS and in four models of parenchymal reaction. Glia 1993;7:34–40.
Reid DM, Perry VH, Andersson PB, Gordon S: Mitosis and apoptosis of microglia in vivo induced by an anti-CR3 antibody which crosses the blood-brain barrier. Neuroscience 1993;56:529–533.
Becher B, Antel JP: Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia 1996;18:1–10.
Cui YH, Le Y, Gong W, et al: Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells. J Immunol 2002;168:434–442.
Giulian D, Chen J, Ingeman JE, George JK, Noponen M: The role of mononuclear phagocytes in wound healing after traumatic injury to adult mammalian brain. J Neurosci 1989;9:4416–4429.
Amat JA, Ishiguro H, Nakamura K, Norton WT: Phenotypic diversity and kinetics of proliferating microglia and astrocytes following cortical stab wounds. Glia 1996;16:368–382.
Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB: Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 1988;8:2485–2490.
Graeber MB, Streit WJ, Kreutzberg GW: Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells. J Neurosci Res 1988;21:18–24.
Chao CC, Hu S, Sheng WS, Bu D, Bukrinsky MI, Peterson PK: Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 1996;16:276–284.
Kaltschmidt C, Kaltschmidt B, Lannes-Vieira J, et al: Transcription factor NF-kappa B is activated in microglia during experimental autoimmune encephalomyelitis. J Neuroimmunol 1994;55:99–106.
Sadik K, Wilcock G: The increasing burden of Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 3:S75-S79.
Dickson DW: The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321–339.
Scheff SW, Price DA: Synaptic density in the inner molecular layer of the hippocampal dentate gyrus in Alzheimer disease. J Neuropathol Exp Neurol 1998;57:1146–1153.
Selkoe D: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741–766.
Wegiel J, Wisniewski HM, Dziewiatkowski J, et al: The origin of amyloid in cerebral vessels of aged dogs. Brain Res 1995;705:225–234.
Wisniewski KE, Wisniewski HM, Wen GY: Occurrance of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17: 278–282.
Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ: Evidence that the 42- and 40-amino acid forms of amyloid β protein are generated from the β-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA 1996;93:13,170–13,175.
Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;399 (Suppl 6738):A23-A31.
Eikelenboom P, Rozemuller JM, van Muiswinkel FL: Inflammation and Alzheimer's disease: relationships between pathogenic mechanisms and clinical expression. Exp Neurol 1998;154:89–98.
Cotter RL, Burke WJ, Thomas VS, Potter JF, Zheng J, Gendelman HE: Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. J Leukoc Biol 1999;65:416–427.
McGeer PL, McGeer EC: Inflammation of the brain in Alzheimer's disease: implications for therapy. J Leukoc Biol 1999;65:409–415.
McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285–1291.
Uchihara T, Akiyama H, Kondo H, Ikeda K: Activated microglial cells are colocalized with perivascular deposits of amyloid-β protein in Alzheimer's disease brain. Stroke 1997;28:1948–1950.
Rogers J, Lue LF: Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem Int 2001; 39:333–340.
Lue LF, Rydel R, Brigham EF, et al: Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001;35:72–79.
Walker DG, Kim SU, McGeer PL: Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J Neurosci Res 1995;40:478–493.
Shen Y, Li R, McGeer EG, McGeer PL: Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res 1997;769:391–395.
Strohmeyer R, Shen Y, Rogers J: Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res 2000;81:7–18.
Walker DG, Lue LF, Beach TG: Gene expression profiling of amyloid beta peptide-stimulated human postmortem brain microglia. Neurobiol Aging 2001;22: 957–966.
Fiala M, Zhang L, Gan X, et al: Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med 1998;4: 480–489.
Haga S, Ikeda K, Sato M, Ishii T: Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res 1993;601:88–94.
Haga S, Aizawa T, Ishii T, Ikeda K: Complement gene expression in mouse microglia and astrocytes in culture: comparisons with mouse peritoneal macrophages. Neurosci Lett 1996;216:191–194.
Weldon DT, Rogers SD, Ghilardi JR, et al: Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 1998;18:2161–2173.
Terry RD, Wisniewski HM: Pathology and pathogenesis of dementia; in Fields WS, (ed): Neurological and Sensory Disorders in the Elderly New York, Stratton, 1975, pp 135–150.
Davis JB, McMurray HF, Schubert D: The amyloid beta-protein of Alzheimer's disease is chemotactic for mononuclear phagocytes. Biochem Biophys Res Commun 1992;189:1096–1100.
El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD: Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996;382:716–719.
Yan SD, Chen X, Fu J, et al: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685–691.
Nakai M, Hojo K, Taniguchi T, et al: PKC and tyrosine kinase involvement in amyloid beta (25–35)-induced chemotaxis of microglia. Neuroreport 1998;9:3467–3470.
McDonald DR, Brunden KR, Landreth GE: Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 1997; 17:2284–2294.
Lorton D: Beta-amyloid-induced IL-1 beta release from an activated human monocyte cell line is calcium- and G-protein-dependent. Mech Ageing Dev 1997;94:99–211.
Lorton D, Schaller J, Lala A, De Nardin E: Chemotactic-like receptors and Abeta peptide induced responses in Alzheimer's disease. Neurobiol Aging 2000;21: 463–473.
Le Y, Gong W, Tiffany HL, et al: Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1, J Neurosci 2001;21:RC123.
Le Y, Murphy PM, Wang JM: Formyl-peptide receptors revisited. Trends Immunol 2002;23:541–548.
Tiffany HL, Lavigne MC, Cui YH, et al: Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain. J Biol Chem 2001;276:23,645–23,652.
Yazawa H, Yu ZX, Takeda K, et al.: Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL 1 and forms fibrillar aggregates in macrophages. FASEB J 2001;15:2454–2462.
Le Y, Gong W, Li B, et al: Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol 1999;163:6777–6784.
Mills J, Reiner PB: Regulation of amyloid precursor protein cleavage. J Neurochem 1999;72:443–460.
Shaffer LM, Dority MD, Gupta-Bansal R, Frederickson RC, Younkin S. G., Brunden KR: Amyloid beta protein (A beta) removal by neuroglial cells in culture. Neurobiol Aging 1995;16:737–745.
Chung H, Brazil MI, Soe TT, Maxfield FR: Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid, beta-peptide by microglial cells. J Biol Chem 1999;274:32,301–32,308.
Weltzien RB, Pachter JS Visualization of beta-amyloid peptide (Abeta) phagocytosis by human mononuclear phagocytes: dependency on Abeta aggregate size. J Neurosci Res 2000;59:522–527.
DeWitt DA, Perry G, Cohen M, Doller C, Silver J: Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol 1998;149: 329–340.
Schenk D, Barbour R, Dunn W, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP, mouse. Nature 1999;400: 173–177.
Hashimoto Y, Niikura T, Tajima H, et al: A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and A β. Proc Natl Acad Sci USA 2001;98:6336–6341.
Tajima H, Niikura T, Hashimoto Y, et al: Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer's disease-related insults. Neurosci Lett 2002;324:227–231.
Ying G, Iribarren P, Zhou Y, et al: Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J Immunol 2004;172:7078–7085.
Nolte C, Moller T, Walter T, Kettenmann H: Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton. Neuroscience 1996;73:1091–1107.
Tanabe S, Heesen M, Yoshizawa I, et al.: Functional expression of CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. J Immunol 1997; 159:905–911.
Boddeke EWGM, Meigel I, Frentzel S, et al: Cultured rat microglia express functional-chemokine receptors. J Neuroimmunol 1999;98:176–184.
Yao J, Harvath L, Gilbert DL, Colton CA: Chemotaxis by a CNS macrophage, the microglia. J Neurosci Res 1990;27:36–42.
Lacy M, Jones J, Whittemore SR, Haviland DL, Wetsel RA, Barnum SR: Expression of the receptor for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. J Neuroimmunol 1995;61:71–78.
Muller-Ladner U, Jones JL, Wetsel RA, Gay S, Raine CS, Barnum SR: Enhanced expression of chemotactic receptors in multiple sclerosis lesions. J Neurol Sci 1996;144:135–141.
Ulevitch RJ, Tobias PS: Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 1999;11:19–22.
Brazil TJ, Rossi AG, Haslett C, McGorum B, Dixon PM, Chilvers ER: Priming induces functional coupling of N-formylmethionyl-leucyl-phenylalanine receptors in equine neutrophils. J Leukoc Biol 1998;63:380–388.
Norgauer J, Eberle M, Fay SP, Lemke HD, Sklar LA: Kinetics of N-formyl peptide receptor up-regulation during stimulation in human neutrophils. J Immunol 1991;146:975–980.
Karlsson A, Markfjall M, Stromberg N, Dahlgren C: Escherichia coli—induced activation of neutrophil NADH-oxidase: lipopolysaccharide and formylated peptides act synergistically to induce release of reactive oxygen metabolites. Infect Immun 1995;63:4606–4612.
Goldman DW, Enkel H, Gifford LA, Chenoweth DE, Rosenbaum JT: Lipopolysaccharide modulates receptors for leukotriene B4, C5a, and formyl-methionyl-leucyl-phenylalanine on rabbit polymorphonnuclear leukocytes. J Immunol 1986;137:1971–1976.
Sica A, Saccani A, Borsatti A, et al: Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J Exp Med 1997; 185:969–974.
Katona IM, Ohura K, Allen JB, Walh LM, Chenoweth DE, Wahl SM: Modulation of monocyte chemotactic function in inflammatory lesions: role of inflammatory mediators. J Immunol 1997;146:708–714.
Sozzani S, Ghezzi S, Iannolo G, et al.: Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med 1998;187:439–444.
Cui YH, Le Y, Zhang X, et al: Up-regulation of formyl peptide receptor 2 (FPR2) in murine microglial cells by TNFα. Neurobiol Dis 2002;10:366–377.
Lacroix S, Feinstein D, Rivest S: The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. Brain Pathol 1998;8:625–640.
Rollins BJ: Chemokines. Blood 1997;90:909–928.
Le Y, Gong W, Shen W, Li B, Dunlop NM, Wang JM: A burgeoning family of biological mediators: chemokines and chemokine receptors. Arch Immunol Ther Exp (Warsz) 2000;48:143–150.
Hull M, Lieb K, Fiebich BL: Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Curr Med Chem 2002;9:83–88.
Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353–356.
Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003;3:23–35.
Mosser DM: The many faces of macrophage activation. J Leukoc Biol 2003;73:209–212.
Tamura S, Hanada M, Ohnishi M, Katsura K, Sasaki M, Kobayashi T: Regulation of stress-activated protein kinase signaling pathways by protein phosphatases. Eur J Biochem 2002;269:1060–1066.
Shanley TP, Vasi N, Denenberg A, Wong HR: The serine/threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling. J Immunol 2001; 166:966–972.
Pahan K, Sheikh FG, Namboodiri AM, Singh I: Inhibitors of protein phosphatase 1 and 2A differentially regulate the expression of inducible nitric-oxide synthase in rat astrocytes and macrophages. J Biol Chem 1998;273:12,219–12,226.
Iribarren P, Cui YH, Le Y, et al: IL-4 down-regulates lipopolysaccharide-induced formyl peptide receptor 2 in murine microglial cells by inhibiting the activation of mitogen-activated protein kinases. J Immunol 2003;171: 5482–5488.
Abbas N, Bednar I, Mix E, et al: Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol 2002; 126:50–57.
Letterio JJ, Roberts AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16: 137–161.
Shull MM, Ormsby I, Kier AB, et al: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693–699.
Kulkarni AB, Huh CG, Becker D, et al: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770–774.
Ulich TR, Yin S, Guo K, Yi ES, Remick D, del Castillo J: Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol 1991;138:1097–1101.
Perrella MA, Hsieh CM, Lee WS, et al: Arrest of endotoxin-induced hypotension by transforming growth factor betal. Proc Natl Acad Sci USA 1996;93:2054–2059.
Imai K, Takeshita A, Hanazawa S: Transforming growth factor-beta inhibits lipopolysaccharide-stimulated expression of inflammatory cytokines in mouse macrophages through downregulation of activation protein 1 and CD14 receptor expression. Infect Immun 2000;68:2418–2423.
Wyss-Coray T, Lin C, Yan F, et al: TGF-betal promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 2001;7:612–618.
Frautschy SA, Yang F, Calderon L, Cole GM: Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Neurobiol Aging 1996;17:311–321.
Le Y, Iribarren P, Gong W, Cui Y, Zhang X, Wang JM: TGF-betal disrupts en dotoxin signaling in microglial cells through Smad3 and MAPK pathways. J Immunol 2004;173:962–968.